-
STAT+: How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition
10 Jul 2025 13:34 GMT
… largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal … in using patents to thwart competition. And the case is being … Regeneron filed a lawsuit accusing Amgen of infringing a key … line.
At the time, Amgen was one of several companies …
-
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight
14 Jul 2025 17:00 GMT
… Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, among others. DelveInsight’s Pharma … and actionable intelligence on their competitors and markets of interest to … them stay ahead of the competition by providing insights into the …
-
Five things for pharma marketers to know: Friday, July 11, 2025
11 Jul 2025 10:17 GMT
… . (STAT News)
Regeneron Pharmaceuticals and Amgen are in the midst of … of using patents to dispel competition. Other companies that sell biosimilar …
-
Creative deal structures help life sciences innovators ride out the macro storm
10 Jul 2025 18:15 GMT
… , and distribution infrastructure. For example, Amgen’s 2019 agreement with BeiGene … granted BeiGene rights to commercialize Amgen’s oncology portfolio in China … manufacturing know-how with a competitor.
Asset purchases coupled with contingent …
-
STAT+: Brawl over Eylea gets biosimilar industry’s attention
10 Jul 2025 13:33 GMT
… fight between Regeneron and Amgen over the blockbuster … Regeneron sued Amgen for patent infringement, Amgen sidestepped the dispute … Regeneron quickly responded, hitting Amgen with another lawsuit in … to delay lower-cost competition.
STAT+ Exclusive Story
…
-
STAT+: Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
10 Jul 2025 13:33 GMT
… largest biotechs — Regeneron Pharmaceuticals and Amgen — is testing the legal … in using patents to thwart competition, STAT writes. The case … Regeneron filed a lawsuit accusing Amgen of infringing a key … line. At the time, Amgen was one of several companies …
-
Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight
10 Jul 2025 01:16 GMT
… of options and limited market competition.
Furthermore, potential therapies are being … Drugs
11.1
Key Cross Competition
11.2
Ponsegromab (PF-06946860 … -alpha inhibitors companies, including AbbVie, Amgen, Johnson & Johnson (through Janssen …
-
Two More Pairs of Denosumab Biosimilars Enter US Market
09 Jul 2025 23:14 GMT
… reached a global settlement with Amgen regarding its denosumab biosimilars.
Just … reached a global settlement with Amgen concerning its denosumab biosimilars. To … cost.
Growing Denosumab Competition
The pairs of denosumab competitors follow the launches …
-
Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre
09 Jul 2025 19:23 GMT
… , setting it apart from COPD competitors for its ability to both … COPD and an eosinophilic phenotype. Amgen and AstraZeneca have hopes for …
-
Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade
09 Jul 2025 17:58 GMT
… COVID-related products and generic competition 2022 Amgen Horizon $27.8 Buyout …